A coronavirus vaccine from Germany’s BioNTech has yielded positive trial results, generating immune defences in participants that were stronger than those of the average recovered Covid-19 patient, according to preliminary data released by the company.
In a clinical study run with pharmaceuticals group Pfizer in the US, 24 people between the ages of 18 and 55 who received two doses of the vaccine had “significantly elevated” antibodies within four weeks of their first injection.
In total, there were 45 people in the study, with some receiving placebos and others getting higher doses of the vaccine.
您已閱讀13%（604字），剩餘87%（4102字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。